According to Sarepta Therapeutics 's latest financial reports the company's total debt is $1.39 B. A companyโs total debt is the sum of all current and non-current debts.
Year | Total debt | Change |
---|---|---|
2023-12-31 | $1.39 B | -13.64% |
2022-12-31 | $1.61 B | 40.22% |
2021-12-31 | $1.15 B | 7.51% |
2020-12-31 | $1.07 B | 47.04% |
2019-12-31 | $0.72 B | 73.49% |
2018-12-31 | $0.42 B | -2.44% |
2017-12-31 | $0.43 B | 2569.05% |
2016-12-31 | $16.15 M | -30.98% |
2015-12-31 | $23.39 M | 269.75% |
2014-12-31 | $6.32 M | 279.38% |
2013-12-31 | $1.66 M | -5.07% |
2012-12-31 | $1.75 M | -4.61% |
2011-12-31 | $1.84 M | -4.21% |
2010-12-31 | $1.92 M | -3.9% |
2009-12-31 | $2 M | -22.74% |
2008-12-31 | $2.59 M | 20.93% |
2007-12-31 | $2.14 M |
Company | Total debt | differencediff. | Country |
---|---|---|---|
Gilead Sciences GILD | $24.98 B | 1,688.86% | ๐บ๐ธ USA |
PTC Therapeutics
PTCT | $2.22 B | 59.59% | ๐บ๐ธ USA |
Novavax NVAX | $0.22 B | -83.60% | ๐บ๐ธ USA |
Alnylam Pharmaceuticals
ALNY | $1.30 B | -6.54% | ๐บ๐ธ USA |
Insmed INSM | $1.20 B | -13.80% | ๐บ๐ธ USA |
BioCryst Pharmaceuticals
BCRX | $0.82 B | -40.93% | ๐บ๐ธ USA |
Avidity Biosciences RNA | $9.85 M | -99.29% | ๐บ๐ธ USA |